Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation

NCT02834364 is registered in ClinicalTrials.gov with University of Heidelberg Medical Center as lead sponsor.

NCT NCT02834364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02834364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation
Lead sponsor
University of Heidelberg Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
March 29, 2023
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

patients with brafv600 e or brafv600k mutation, relapsed or refractory multiple myeloma